ArticleMedicine2026
Systemic inflammatory biomarkers and their partial role in the association between diabetes and sarcopenia: A population-based study using NHANES data.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mediating role of inflammatory biomarkers in the association between diabetes and sarcopenia remains poorly quantified in general populations. This study aims to investigate this relationship and quantify the mediating effects of systemic inflammatory indicators. This cross-sectional study included 11,190 adults from the National Health and Nutrition Examination Survey 2011 to 2018. Weighted logistic regression and subgroup analyses were used to assess the association between diabetes and sarcopenia, defined by the Foundation for the National Institutes of Health criteria (appendicular skeletal muscle mass/body mass index). Mediation analysis with bootstrapping was performed to evaluate the mediating roles of white blood cells, neutrophils, lymphocytes, neutrophil-to-lymphocyte ratio, and Systemic Immune-Inflammation Index. Diabetes was significantly associated with an increased risk of sarcopenia (odds ratio = 1.48, 95% confidence interval: 1.03-2.13, P = .042) after full adjustment. Mediation analysis revealed that white blood cells, neutrophils, lymphocytes, neutrophil-to-lymphocyte ratio, and Systemic Immune-Inflammation Index mediated 28.48%, 26.58%, 7.36%, 6.54%, and 10.17% of this association, respectively (all P < .05). Diabetes is positively associated with sarcopenia risk, partially mediated by systemic inflammation. Readily available inflammatory biomarkers may aid in identifying high-risk diabetic patients for sarcopenia prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.